CR20150555A - Nuevos derivados de pirrolo[2,3-d]pirimidina - Google Patents

Nuevos derivados de pirrolo[2,3-d]pirimidina

Info

Publication number
CR20150555A
CR20150555A CR20150555A CR20150555A CR20150555A CR 20150555 A CR20150555 A CR 20150555A CR 20150555 A CR20150555 A CR 20150555A CR 20150555 A CR20150555 A CR 20150555A CR 20150555 A CR20150555 A CR 20150555A
Authority
CR
Costa Rica
Prior art keywords
pirrolo
pyrimidine
new derivatives
compound
formula
Prior art date
Application number
CR20150555A
Other languages
English (en)
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CR20150555A publication Critical patent/CR20150555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a un compuesto de la fórmula (I); en la que A y de R1 a R3 tienen los significados definidos en la descripción y en las reivindicaciones. El compuesto de la fórmula (I) puede utilizarse como medicamento.
CR20150555A 2013-05-02 2015-10-14 Nuevos derivados de pirrolo[2,3-d]pirimidina CR20150555A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166296 2013-05-02
PCT/EP2014/058648 WO2014177527A1 (en) 2013-05-02 2014-04-29 Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists

Publications (1)

Publication Number Publication Date
CR20150555A true CR20150555A (es) 2015-11-20

Family

ID=48190401

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150555A CR20150555A (es) 2013-05-02 2015-10-14 Nuevos derivados de pirrolo[2,3-d]pirimidina

Country Status (34)

Country Link
US (1) US9580435B2 (es)
EP (1) EP2991988B1 (es)
JP (1) JP6454689B2 (es)
KR (1) KR20160002857A (es)
CN (1) CN105164133B (es)
AR (1) AR096153A1 (es)
AU (1) AU2014261546B2 (es)
BR (1) BR112015027394A8 (es)
CA (1) CA2907691A1 (es)
CL (1) CL2015003196A1 (es)
CR (1) CR20150555A (es)
CY (1) CY1119114T1 (es)
DK (1) DK2991988T3 (es)
EA (1) EA028123B1 (es)
ES (1) ES2635632T3 (es)
HR (1) HRP20171099T1 (es)
HU (1) HUE035333T2 (es)
IL (1) IL242162B (es)
LT (1) LT2991988T (es)
MA (1) MA38555B1 (es)
MX (1) MX373855B (es)
MY (1) MY182237A (es)
NZ (1) NZ712030A (es)
PE (1) PE20160039A1 (es)
PH (1) PH12015502409B1 (es)
PL (1) PL2991988T3 (es)
PT (1) PT2991988T (es)
RS (1) RS56313B1 (es)
SG (1) SG11201509029PA (es)
SI (1) SI2991988T1 (es)
TW (1) TWI680129B (es)
UA (1) UA116801C2 (es)
WO (1) WO2014177527A1 (es)
ZA (1) ZA201507008B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3943497A1 (en) 2013-09-06 2022-01-26 F. Hoffmann-La Roche AG Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists
CN107074864B (zh) * 2014-11-07 2019-12-27 豪夫迈·罗氏有限公司 作为大麻素受体2的激动剂的三唑并[4，5-d]嘧啶类
KR20230062680A (ko) * 2016-06-23 2023-05-09 에프. 호프만-라 로슈 아게 2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체
EP3475283B1 (en) 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
EP3475281A1 (en) 2016-06-23 2019-05-01 H. Hoffnabb-La Roche Ag Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives
EP3475280B1 (en) 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
CA3192236A1 (en) 2020-09-10 2022-03-17 Tony Lahoutte Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
TWI270549B (en) * 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
US8722691B2 (en) * 2006-03-30 2014-05-13 Irm Llc Azolopyrimidines as inhibitors of cannabinoid 1 activity
PT2155747E (pt) * 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
US20090062253A1 (en) * 2007-08-31 2009-03-05 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
WO2009051705A1 (en) 2007-10-18 2009-04-23 Merck & Co., Inc. Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
IN2012DN02577A (es) * 2009-10-15 2015-08-28 Pfizer
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
JP2015521652A (ja) 2012-07-04 2015-07-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ カンナビノイド受容体２アゴニストとしての新規アダマンチル誘導体
JP6426619B2 (ja) 2012-12-07 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２アゴニストとして有用なピリジン−２−アミド
EP3357918A1 (en) 2012-12-07 2018-08-08 F. Hoffmann-La Roche AG Novel pyridine derivatives
HRP20171459T1 (hr) 2012-12-07 2017-11-03 F. Hoffmann - La Roche Ag Piridin-2-amidi korisni kao agonisti cb2
PL2928882T3 (pl) 2012-12-07 2017-07-31 F.Hoffmann-La Roche Ag Pochodne pirazyny jako agoniści receptora cb2
UA118666C2 (uk) 2013-03-07 2019-02-25 Ф. Хоффманн-Ля Рош Аг Похідні піразолу
HUE039589T2 (hu) 2013-05-02 2019-01-28 Hoffmann La Roche Purinszármazékok mint CB2 receptor agonisták

Also Published As

Publication number Publication date
MX2015014081A (es) 2015-12-11
PH12015502409A1 (en) 2016-02-22
SI2991988T1 (sl) 2017-09-29
PL2991988T3 (pl) 2017-10-31
MY182237A (en) 2021-01-18
TW201522343A (zh) 2015-06-16
IL242162B (en) 2019-06-30
CL2015003196A1 (es) 2016-06-03
HRP20171099T1 (hr) 2017-10-06
ZA201507008B (en) 2017-08-30
CN105164133B (zh) 2018-02-13
PE20160039A1 (es) 2016-01-28
JP6454689B2 (ja) 2019-01-16
CA2907691A1 (en) 2014-11-06
AU2014261546A1 (en) 2015-09-24
HUE035333T2 (en) 2018-05-02
TWI680129B (zh) 2019-12-21
BR112015027394A2 (pt) 2017-07-25
CY1119114T1 (el) 2018-02-14
MA38555A1 (fr) 2017-09-29
US20160046637A1 (en) 2016-02-18
WO2014177527A1 (en) 2014-11-06
SG11201509029PA (en) 2015-12-30
ES2635632T3 (es) 2017-10-04
AR096153A1 (es) 2015-12-09
PH12015502409B1 (en) 2016-02-22
LT2991988T (lt) 2017-08-10
KR20160002857A (ko) 2016-01-08
AU2014261546B2 (en) 2018-01-18
US9580435B2 (en) 2017-02-28
EA201591939A1 (ru) 2016-03-31
CN105164133A (zh) 2015-12-16
MA38555B1 (fr) 2018-04-30
MX373855B (es) 2020-03-25
DK2991988T3 (en) 2017-08-21
BR112015027394A8 (pt) 2018-01-30
PT2991988T (pt) 2017-07-25
UA116801C2 (uk) 2018-05-10
EP2991988B1 (en) 2017-05-31
JP2016517874A (ja) 2016-06-20
HK1213559A1 (zh) 2016-07-08
EA028123B1 (ru) 2017-10-31
EP2991988A1 (en) 2016-03-09
RS56313B1 (sr) 2017-12-29
NZ712030A (en) 2021-03-26

Similar Documents

Publication Publication Date Title
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
CR20150250A (es) Nuevos derivados de piridina
CR20150447A (es) Nuevos derivados de pirazol
ECSP13013074A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20150440A (es) Nuevos derivados de piridina
CR20150204A (es) Nuevos derivados de piridina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CR20140464A (es) Compuestos de heterociclilo
CR20150511A (es) Nuevos derivados de purina
MX2015014081A (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2).
CL2018001493A1 (es) Nuevos derivados de fenilo
PH12015502118A1 (en) Pyridin-4-yl derivatives
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
CR20160448A (es) Nuevos derivados de piridina
UY35236A (es) Compuestos de [1,2,4]triazol e imidazol sustituidos
DOP2016000021A (es) Imidazotiazol sulfonamidas como nematicidas
MX2015016766A (es) Nuevos derivados de tetrazolona.
CO7200259A2 (es) Nuevos derivados de piridina